Author details

Full Name

Glenn Merlino

Affiliation

Center for Cancer Research, National Cancer Institute, National Institutes of Health

ORCID

Career Start Year

1978

Papers

238

H Index

Expertise

CM4AI Collaborator

Prashant Mali (CM4AI)

PMID	Paper Title	Journal Title	Published Year
36824269	PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6.	iScience	2023
38067178	CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.	Cells	2023
36824269	PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6.	iScience	2023
37333132	Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms.	bioRxiv	2023
37314923	Using the single-cell imaging system and orthotropic footpad injection to establish mouse models for experimental and spontaneous melanoma metastasis.	STAR Protoc	2023
37371090	Ez-Metastasizing: The Crucial Roles of Ezrin in Metastasis.	Cells	2023
37301330	Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response.	Pharmacol Ther	2023
37173324	Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.	Nat Commun	2023
38067178	CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.	Cells	2023
37314923	Using the single-cell imaging system and orthotropic footpad injection to establish mouse models for experimental and spontaneous melanoma metastasis.	STAR Protoc	2023
37173324	Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.	Nat Commun	2023
37371090	Ez-Metastasizing: The Crucial Roles of Ezrin in Metastasis.	Cells	2023
37333132	Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms.	bioRxiv	2023
37301330	Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response.	Pharmacol Ther	2023
35180384	Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies.	Cancer Cell	2022
35912544	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.	Pigment Cell Melanoma Res	2022
35954330	PTEN Dual Lipid- and Protein-Phosphatase Function in Tumor Progression.	Cancers (Basel)	2022
35953723	Publisher Correction: A T cell resilience model associated with response to immunotherapy in multiple tumor types.	Nat Med	2022
35501486	A T cell resilience model associated with response to immunotherapy in multiple tumor types.	Nat Med	2022
36347238	The Hitchhiker's Guide across a Waddington's landscape of melanoma.	Dev Cell	2022
35718707	Making a mouse out of a molehill: how precision modeling repurposes drugs for congenital giant nevi.	Trends Cancer	2022
35317524	A novel PD-L1-targeted shark V<sub>NAR</sub> single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer.	Mol Ther Oncolytics	2022
35180384	Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies.	Cancer Cell	2022
35501486	A T cell resilience model associated with response to immunotherapy in multiple tumor types.	Nat Med	2022
35718707	Making a mouse out of a molehill: how precision modeling repurposes drugs for congenital giant nevi.	Trends Cancer	2022
35954330	PTEN Dual Lipid- and Protein-Phosphatase Function in Tumor Progression.	Cancers (Basel)	2022
35953723	Publisher Correction: A T cell resilience model associated with response to immunotherapy in multiple tumor types.	Nat Med	2022
36347238	The Hitchhiker's Guide across a Waddington's landscape of melanoma.	Dev Cell	2022
35912544	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.	Pigment Cell Melanoma Res	2022
35317524	A novel PD-L1-targeted shark V<sub>NAR</sub> single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer.	Mol Ther Oncolytics	2022
33414132	The State of Melanoma: Emergent Challenges and Opportunities.	Clin Cancer Res	2021
33545064	Melanoma models for the next generation of therapies.	Cancer Cell	2021
34282258	PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN.	NPJ Precis Oncol	2021
33888600	Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.	Mol Cancer Res	2021
33568347	Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.	Clin Cancer Res	2021
34343493	A UVB-responsive common variant at chromosome band 7p21.1 confers tanning response and melanoma risk via regulation of the aryl hydrocarbon receptor, AHR.	Am J Hum Genet	2021
33024267	Nme1 and Nme2 genes exert metastasis-suppressor activities in a genetically engineered mouse model of UV-induced melanoma.	Br J Cancer	2021
33414132	The State of Melanoma: Emergent Challenges and Opportunities.	Clin Cancer Res	2021
34389658	Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.	Clin Cancer Res	2021
34433909	Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.	Oncogene	2021
34941392	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.	Science	2021
34642183	Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages.	Cancer Res	2021
35121961	Creating opportunities in cancer research.	Nat Cancer	2021
34635800	Correction: Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.	Oncogene	2021
33545064	Melanoma models for the next generation of therapies.	Cancer Cell	2021
33568347	Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.	Clin Cancer Res	2021
33888600	Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.	Mol Cancer Res	2021
34941392	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.	Science	2021
35121961	Creating opportunities in cancer research.	Nat Cancer	2021
34433909	Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.	Oncogene	2021

1 - 50 of 476

Shruthy Suresh

Memorial Sloan Kettering Cancer Center

Career Start Year 2013

Number of shared co-authors 2

Susan L Woods

Adelaide Medical School, University of Adelaide

Career Start Year 2002

Number of shared co-authors 8

Qingxia Wei

Princess Margaret Cancer Centre, University Health Network and University of Toronto

Career Start Year 2000

Number of shared co-authors 1

Jianjun Shen

The University of Texas MD Anderson Cancer Center

Career Start Year 1998

Number of shared co-authors 5

Yaoqi Alan Wang

The University of Texas MD Anderson Cancer Center

Career Start Year 1997

Number of shared co-authors 5

Alexander D Borowsky

University of California Davis Health

Career Start Year 1995

Number of shared co-authors 5

Jan Paul Medema

Oncode Institute

Career Start Year 1993

Number of shared co-authors 5

Julien Sage

Department of Pediatrics Stanford University Stanford California USA.

Career Start Year 1993

Number of shared co-authors 3

Eve Shinbrot

Baylor College of Medicine

Career Start Year 1993

Number of shared co-authors 3

James DeGregori

University of Colorado Anschutz Medical Campus

Career Start Year 1991

Number of shared co-authors 1

David A Largaespada

University of Minnesota

Career Start Year 1990

Number of shared co-authors 15

Roger Chammas

Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina de Sao Paulo

Career Start Year 1989

Number of shared co-authors 0

Rainer Heuchel

Karolinska Institutet

Career Start Year 1988

Number of shared co-authors 0

Enzo Medico

Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS

Career Start Year 1988

Number of shared co-authors 2

Daniel S Peeper

Netherlands Cancer Institute

Career Start Year 1987

Number of shared co-authors 14

William C Hahn

Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute

Career Start Year 1987

Number of shared co-authors 14

Louis Gaboury

Institute for Research in Immunology and Cancer (IRIC), University of Montreal

Career Start Year 1986

Number of shared co-authors 1

Anthony E Oro

Stanford University

Career Start Year 1985

Number of shared co-authors 0

Colin R Goding

Ludwig Institute for Cancer Research, University of Oxford

Career Start Year 1983

Number of shared co-authors 16

Francisco X Real

Spanish National Cancer Research Centre-CNIO

Career Start Year 1983

Number of shared co-authors 12

Edison T Liu

USA The Jackson Laboratory Cancer Center

Career Start Year 1982

Number of shared co-authors 10

David M Thomas

Garvan Institute of Medical Research

Career Start Year 1980

Number of shared co-authors 15

Alexander Kamb

Inc. 30301 Agoura Rd.

Career Start Year 1979

Number of shared co-authors 3

Michael C Ostrowski

Hollings Cancer Center, Medical University of South Carolina

Career Start Year 1979

Number of shared co-authors 1

Evelyn Flynn

Boston Children's Hospital

Career Start Year 1978

Number of shared co-authors 1

Webster K Cavenee

Ludwig Institute for Cancer Research, University of California San Diego

Career Start Year 1977

Number of shared co-authors 8

Lawrence A Donehower

Baylor College of Medicine

Career Start Year 1975

Number of shared co-authors 7

Menashe Bar-Eli

The University of Texas MD Anderson Cancer Center

Career Start Year 1975

Number of shared co-authors 10

Hartmut Land

University of Rochester Medical Center, Wilmot Cancer Institute

Career Start Year 1974

Number of shared co-authors 1

William E Grizzle

University of Alabama at Birmingham

Career Start Year 1974

Number of shared co-authors 1

row(s) 1 - 30 of 30

Chi-Ping Day

Center for Cancer Research, National Cancer Institute

Co-authored papers 34

Frances P Noonan

The George Washington University Medical Center

Co-authored papers 16

M Raza Zaidi

Northwell Health Cancer Institute

Co-authored papers 13

Edward C De Fabo

The George Washington University Medical Center

Co-authored papers 13

Eva P??rez-Guijarro

National Cancer Institute, National Institutes of Health (NIH)

Co-authored papers 12

Helen T Michael

National Cancer Institute, National Institutes of Health

Co-authored papers 11

Kerrie L Marie

The University of Manchester

Co-authored papers 9

Paul S Meltzer

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Co-authored papers 7

Chand Khanna

National Cancer Institute, National Institutes of Health

Co-authored papers 6

Lee J Helman

Osteosarcoma Institute

Co-authored papers 6

Pravin J Mishra

Robert Wood Johnson Medical School, The State University of New Jersey

Co-authored papers 6

Andrew E Aplin

Thomas Jefferson University

Co-authored papers 5

Andrzej T Slominski

University of Alabama at Birmingham

Co-authored papers 5

Susan R Davis

Co-authored papers 5

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Co-authored papers 5

Maxwell P Lee

National Cancer Institute, National Institutes of Health

Co-authored papers 5

Marcus Bosenberg

Yale School of Medicine

Co-authored papers 5

Cari Graff-Cherry

Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research

Co-authored papers 4

Michael A Davies

The University of Texas MD Anderson Cancer Center